|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
Israel bans Juul e-cigarettes citing 'grave' public health risk [Reuters]
|
|
|
|
|
|
In
a statement Tuesday, Juul Labs Inc said it was “incredibly
disappointed” with what it called a “misguided” decision by the Israeli
government. The San Francisco company said it planned to appeal the ban,
adding that its devices provide smokers “a true alternative to
combustible cigarettes.”
|
|
|
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
|
Cervical Cancer: Screening [USPSTF]
|
|
|
|
|
|
The
USPSTF recommends screening for cervical cancer every 3 years with
cervical cytology alone in women aged 21 to 29 years. For women aged 30
to 65 years, the USPSTF recommends screening every 3 years with cervical
cytology alone, every 5 years with high-risk human papillomavirus
(hrHPV) testing alone, or every 5 years with hrHPV testing in
combination with cytology (cotesting).
|
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
|
Overlooked molecule might be key to how well cancer-fighting CAR-T cells work [STAT]
|
|
|
|
|
|
Although
the authors of the new study, in Science Signaling, are careful not to
say one co-stimulatory domain is better than the other, their analyses
of CAR-Ts in test tubes concluded that those with the co-stimulatory
molecule CD28 attacked cancer cells more quickly and more intensely than
those with the co-stimulatory molecule 4-1BB.
|
|
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim [ESMO]
|
|
|
|
|
|
On
26 July 2018, the European Medicines Agency’s (EMA’s) Committee for
Medicinal Products for Human Use (CHMP) adopted a positive opinion,
recommending granting a marketing authorisation for the medicinal
products Pelgraz and Udenyca, intended to reduce the duration of
neutropenia and the incidence of febrile neutropenia due to
chemotherapy.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.10.1 Politiques (USA)
|
|
|